Britain’s health costs watchdog is asking Bayer for more information on its anti-clotting drug Xarelto before deciding whether to recommend it for use on the state health service.
Britain’s health costs watchdog is asking Bayer for more information on its anti-clotting drug Xarelto before deciding whether to recommend it for use on the state health service.
